Janux Therapeutics (JANX) Current Leases (2021 - 2026)

Janux Therapeutics (JANX) has reported Current Leases for 6 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases rose 36.5% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (up 36.5% YoY), while the FY2025 annual figure was $2.4 million, up 36.82% from the prior year.
• Current Leases climbed to $2.5 million in Q1 2026 per JANX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Current Leases topped out at $2.5 million in Q1 2026 and bottomed at $88000.0 in Q2 2022.
• Historically, Current Leases has averaged $1.5 million across 5 years, with a median of $1.6 million in 2024.
• Annual changes were most pronounced in 2023 — Current Leases soared 1500.0% — and 2025, when it increased 14.91%.
• Janux Therapeutics' Current Leases stood at $763000.0 in 2022, then surged by 98.82% to $1.5 million in 2023, then rose by 15.29% to $1.7 million in 2024, then surged by 36.82% to $2.4 million in 2025, then rose by 3.3% to $2.5 million in 2026.
• Business Quant data shows JANX's Current Leases at $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.